Clinical manifestations and impact on patient quality of life amid diagnosis and management of CLL and SLL are discussed. This is a video synopsis/summary of a Peer Exchange involving Ryan Haumschild, ...

Jaypirca showed superior PFS and lower discontinuation rates compared to standard treatments in CLL/SLL patients. Jaypirca reduced the risk of progression or death by 46% to 52% and had a favorable ...

Jaypirca showed higher overall response rates than Imbruvica in both treatment-naive and relapsed/refractory CLL/SLL populations. Progression-free survival trends favored Jaypirca, especially in ...

Please provide your email address to receive an email when new articles are posted on . ORLANDO — In this video, Matthew S. Davids, MD, said data from the BRUIN-313 trial supports front-line approval ...

Retreatment with venetoclax and rituximab in CLL patients achieved 100% response rates and prolonged progression-free survival. This new study reveals venetoclax and rituximab effectively treat ...

Researchers sought to compare the safety and efficacy of pirtobrutinib monotherapy vs bendamustine plus rituximab among treatment-naïve patients with CLL/SLL.

Copiktra (duvelisib) is a type of cancer treatment for certain people with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL). CLL and SLL are slow-growing cancers that affect a ...

At a median duration of follow-up of 6.6 months, treatment with pirtobrutinib reduced the risk of progression or death by 42%. The Food and Drug Administration (FDA) has approved Jaypirca ® ...

Breyanzi offers a personalized treatment option delivered as a one-time infusion that provides deep and durable responses for patients with relapsed or refractory CLL or SLL who have historically had ...

Please provide your email address to receive an email when new articles are posted on . In the BRUIN CLL-313 trial, researchers compared pirtobrutinib (Jaypirca, Eli Lilly & Co.) vs. bendamustine plus ...

The US Food and Drug Administration (FDA) has granted accelerated approval to pirtobrutinib (Jaypirca; Eli Lilly and Company) for third-line or later treatment in adults with chronic lymphocytic ...